Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) opened an affiliated sleep testing and treatment center in Auburn Hills, Michigan on Dec. 16, 2025, expanding its commercial affiliation model beyond Las Vegas.

The center operates under a July agreement with MISleep Solutions, where Vivos built out the facility, staffed and trained personnel, and will provide its FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea (OSA). Vivos positions the affiliation model as capital-efficient versus outright acquisitions while preserving accretive economics and expects to pursue similar partnerships nationwide.

Key Figures

Q3 2025 revenue $6.8M Quarter ended September 30, 2025 per 10-Q

Q3 2025 net loss $5.4M Quarter ended September 30, 2025 per 10-Q

Cash balance $3.1M As of September 30, 2025 per 10-Q

Total liabilities $23.1M As of September 30, 2025 per 10-Q

SCN acquisition cost $8.7M Acquisition of The Sleep Center of Nevada per 10-Q

Senior secured note $8.3M Debt used to fund SCN acquisition per 10-Q

ATM capacity $3,583,686 Maximum aggregate offering under ATM prospectus supplement

Public float $35,068,378 Based on 7,477,266 non-affiliate shares at $4.69 (Aug 26, 2025)

Market Reality Check

$2.02 Last Close

Volume Volume 220,429 is 1.68x the 20-day average of 131,268 ahead of this news. high

Technical Shares at $2.02 sit near the 52-week low of $1.98, well below the $3.27 200-day MA and far from the $7.95 52-week high.

Peers on Argus 2 Up

VVOS was down 2.42% while momentum-screened peers like ADGM and RBOT were moving up, and core device peers showed mixed moves, suggesting stock-specific trading rather than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 19	Q3 2025 results	Positive	-4.5%	Strong revenue growth from SCN acquisition but continued operating loss.
Nov 19	Earnings schedule	Neutral	-4.5%	Announcement of timing for Q3 results and conference call.
Sep 30	Clinical data update	Positive	-1.0%	Pediatric ADHD and OSA data showing large symptom and airway improvements.
Sep 17	Clinical trial results	Positive	+3.5%	Landmark pediatric OSA trial with strong response and resolution rates.
Aug 19	Q2 2025 earnings	Negative	-3.3%	Q2 revenue decline vs. prior year and higher operating expenses.

Pattern Detected

Recent positive clinical and revenue updates often met with flat to negative next-day moves, indicating a tendency for cautious or selling reactions even on favorable news.

Recent Company History

Over the last six months, VVOS reported expanding revenue from its sleep-center strategy, including The Sleep Center of Nevada acquisition and a strong Q3 2025 revenue ramp, but results still showed operating losses. Two pediatric OSA clinical data releases in September 2025 highlighted strong efficacy for the DNA appliance, with one event drawing a modest positive price reaction. Earnings-related releases in August and November 2025 saw negative follow-through. Today’s affiliation-based expansion in Michigan fits the ongoing shift toward sleep-center and management-agreement models.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-05

The company has an active S-3/A shelf filed on Sep 05, 2025, with at least one usage via a 424B5 prospectus supplement on Oct 24, 2025 tied to its at-the-market program, indicating an established mechanism for future equity issuance.

Market Pulse Summary

This announcement highlights Vivos’ continued rollout of a capital-efficient affiliation model, adding an Auburn Hills, Michigan sleep center to extend its diagnostic and treatment footprint. It connects to earlier moves like the Nevada acquisition and management agreements, reinforcing a shift toward sleep-center based distribution. Filings show growing revenue alongside ongoing net losses and financing activity, so monitoring future center performance, operating cash needs, and any additional ATM usage remains important.

Key Terms

obstructive sleep apnea medical

"sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

fda-cleared regulatory

"bring Vivos’ proprietary line of FDA-cleared diagnostic and therapeutic products"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. Not financial advice.

Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep Solutions

LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening of its latest sleep testing and treatment center near Detroit in Auburn Hills, Michigan.

This new center represents an extension of Vivos’ sleep center affiliation model—a capital-efficient and scalable version of Vivos’ growing operations in Las Vegas, Nevada. This model can take the form of contractual alliances, such as in Auburn Hills, or outright acquisitions of sleep medical practices, such as the one Vivos completed this past summer in Las Vegas with the acquisition of The Sleep Center of Nevada.

This grand opening in Detroit signals the continuation of Vivos’ national expansion strategy to leverage commercial affiliations with high-volume sleep clinics and physician-owned sleep and other medical practices to bring Vivos’ proprietary line of FDA-cleared diagnostic and therapeutic products and services to tens of millions suffering from OSA and related health conditions. Many OSA patients who experience the full diagnostic and therapeutic treatment regimen from Vivos-trained providers see their OSA and related symptoms diminish or resolve in less than a year.

Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, explained the importance of this announcement, stating “Over the past decade, sleep testing centers and sleep specialists have experienced tremendous pricing pressure from both government and commercial insurance payers. As a result, many sleep testing labs have either closed down or sold out to larger groups. For those who have survived, their labs and practices have become dependent on seeing a growing number of patients at much lower reimbursement rates. Many of them have also become disenchanted by the industry’s 45-year-old, go-to solution of CPAP as the primary front-line treatment for over 90% of their patients with OSA. By affiliating with established sleep centers and practitioners, Vivos brings an exciting and highly differentiated set of diagnostic and treatment options to their patients, which is expected to yield additional revenues and higher margin services revenue for Vivos. This dynamic creates a powerful win/win solution for providers, OSA patients, and Vivos.”

The opening of the Auburn Hills center follows Vivos’ execution of an agreement with MISleep Solutions, LLC in July to provide certain management and support services along with our full suite of Vivos treatments and services to OSA patients. Pursuant to the agreement, Vivos has built out and equipped the center, hired and trained providers and support personnel, and prepared for the grand opening. This contractual strategic alliance structure is less capital-intensive compared to the outright acquisition of sleep centers, while preserving the vast majority of the accretive economics associated with Vivos’ line of diagnostic and therapeutic products and services. Vivos looks forward to working closely with MISleep Solutions to expand the use of Vivos’ products and services to additional sleep clinics and medical specialists throughout the metro Detroit area.

Vivos is also currently in talks with other sleep center groups and sleep specialist physicians across the country to establish similar affiliations.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children. 

OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA. 

Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com. 

Cautionary Note Regarding Forward-Looking Statements

This press release, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the actual future impact on Vivos’ revenue and profitability of its contractual alliance with MISleep Solutions and (ii) the anticipated benefits and potential expansion of Vivos’ marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual results from opening the Auburn Hills, Michigan sleep center described herein on Vivos’ future revenues and results of operations or the anticipated benefits of the Company’s marketing and distribution model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) market and other conditions that could impact Vivos’ business or ability to obtain financing, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Media Inquiries: 
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com

FAQ

What did Vivos (VVOS) announce on Dec. 16, 2025 about the Auburn Hills sleep center?

Vivos announced the grand opening of an affiliated sleep testing and treatment center in Auburn Hills, Michigan, operating under a July agreement with MISleep Solutions.

How will the Auburn Hills affiliation with MISleep Solutions affect Vivos (VVOS) operations?

Vivos built, staffed, and trained the center and will provide its FDA-cleared diagnostic and therapeutic products, expanding its affiliation-based, capital-efficient model.

Does the Auburn Hills center represent an acquisition by Vivos (VVOS)?

No; the Auburn Hills center is a contractual strategic affiliation with MISleep Solutions, not an outright acquisition.

What is Vivos’ growth strategy described in the Dec. 16, 2025 announcement?

The company plans national expansion by affiliating with high-volume sleep clinics and physician-owned practices to deploy its diagnostic and therapeutic OSA products.

What services will Vivos (VVOS) provide at the new Auburn Hills sleep center?

Vivos will supply its full suite of FDA-cleared diagnostic and therapeutic products, management and support services, plus trained providers and support personnel.

Will Vivos pursue additional sleep center affiliations after Auburn Hills?

Yes; the company said it is in talks with other sleep center groups and sleep specialist physicians across the U.S. to establish similar affiliations.